Zoetis Inc. (ZTS) P/E Ratio History
Deep ValueTrading at 12.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Zoetis Inc. (ZTS) trades at a price-to-earnings ratio of 12.7x, with a stock price of $76.29 and trailing twelve-month earnings per share of $6.26.
The current P/E is 64% below its 5-year average of 35.1x. Over the past five years, ZTS's P/E has ranged from a low of 19.6x to a high of 57.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, ZTS trades at a 46% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 1.06 (P/E divided by 10% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, ZTS trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZTS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZTS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ZTS P/E vs Peers
Animal health pharmaceuticals and vaccines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 161.4 | - | +107% | |
| $1B | 27.8 | 3.73 | +1883%Best | |
| $45B | 43.6 | 3.05 | +23% | |
| $318B | 17.7 | 0.83Best | +8% | |
| $137B | 17.7 | - | -4% | |
| $450B | 107.4 | - | -1% | |
| $1.2T | 53.8 | 1.87 | +96% | |
| $118B | 16.8Lowest | - | +178% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ZTS Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $118.13 | $6.03 | 19.6x | -49% |
| FY2025 Q4 | Dec 31 2025 | $125.82 | $6.02 | 20.9x | -45% |
| FY2025 Q3 | - | $146.32 | $5.94 | 24.6x | -35% |
| FY2025 Q2 | Jun 30 2025 | $155.95 | $5.81 | 26.8x | -29% |
| FY2025 Q1 | Mar 31 2025 | $164.65 | $5.57 | 29.6x | -22% |
| FY2024 Q4 | - | $162.93 | $5.47 | 29.8x | -22% |
| FY2024 Q3 | Sep 30 2024 | $195.38 | $5.32 | 36.7x | -4% |
| FY2024 Q2 | Jun 30 2024 | $173.36 | $5.11 | 33.9x | -11% |
| FY2024 Q1 | Mar 31 2024 | $169.21 | $5.19 | 32.6x | -14% |
| FY2023 Q4 | Dec 31 2023 | $197.37 | $5.07 | 38.9x | +2% |
| FY2023 Q3 | Sep 30 2023 | $173.98 | $4.92 | 35.4x | -7% |
| FY2023 Q2 | Jun 30 2023 | $172.21 | $4.76 | 36.2x | -5% |
| FY2023 Q1 | Mar 31 2023 | $166.44 | $4.43 | 37.6x | -1% |
| FY2022 Q4 | Dec 31 2022 | $146.55 | $4.50 | 32.6x | -14% |
| FY2022 Q3 | Sep 30 2022 | $148.29 | $4.38 | 33.9x | -11% |
| FY2022 Q2 | - | $171.89 | $4.41 | 39.0x | +2% |
| FY2022 Q1 | - | $188.59 | $4.36 | 43.3x | +14% |
| FY2021 Q4 | Dec 31 2021 | $244.03 | $4.27 | 57.1x | +50% |
| FY2021 Q3 | - | $194.14 | $4.15 | 46.8x | +23% |
| FY2021 Q2 | Jun 30 2021 | $186.36 | $3.99 | 46.7x | +23% |
| FY2021 Q1 | Mar 31 2021 | $157.48 | $3.71 | 42.4x | +12% |
| FY2020 Q4 | - | $165.50 | $3.42 | 48.4x | +27% |
| FY2020 Q3 | Sep 30 2020 | $165.37 | $3.47 | 47.7x | +25% |
| FY2020 Q2 | - | $137.04 | $3.37 | 40.7x | +7% |
| FY2020 Q1 | - | $117.69 | $3.35 | 35.1x | -8% |
| FY2019 Q4 | - | $132.35 | $3.12 | 42.4x | +11% |
| FY2019 Q3 | Sep 30 2019 | $124.59 | $3.03 | 41.1x | +8% |
| FY2019 Q2 | Jun 30 2019 | $113.49 | $2.84 | 40.0x | +5% |
| FY2019 Q1 | Mar 31 2019 | $100.67 | $2.86 | 35.2x | -8% |
| FY2018 Q4 | Dec 31 2018 | $85.54 | $2.93 | 29.2x | -23% |
| FY2018 Q3 | Sep 30 2018 | $91.56 | $2.38 | 38.5x | +1% |
| FY2018 Q2 | Jun 30 2018 | $85.19 | $2.28 | 37.4x | -2% |
| FY2018 Q1 | Mar 31 2018 | $83.51 | $1.99 | 42.0x | +10% |
| FY2017 Q4 | Dec 31 2017 | $72.04 | $1.75 | 41.2x | +8% |
| FY2017 Q3 | Oct 01 2017 | $63.76 | $1.90 | 33.6x | -12% |
| FY2017 Q2 | Jul 02 2017 | $62.38 | $1.77 | 35.2x | -7% |
| FY2017 Q1 | Apr 02 2017 | $53.37 | $1.72 | 31.0x | -18% |
| FY2016 Q4 | Dec 31 2016 | $53.53 | $1.65 | 32.4x | -15% |
| FY2016 Q3 | Oct 02 2016 | $52.01 | $1.38 | 37.7x | -1% |
| FY2016 Q2 | Jul 03 2016 | $47.45 | $1.28 | 37.1x | -3% |
| FY2016 Q1 | Apr 03 2016 | $44.99 | $0.76 | 59.5x | +56% |
| FY2015 Q4 | - | $47.92 | $0.68 | 70.9x | +86% |
| FY2015 Q3 | Sep 27 2015 | $42.51 | $0.89 | 48.0x | +26% |
| FY2015 Q2 | Jun 28 2015 | $48.62 | $0.84 | 58.2x | +53% |
| FY2015 Q1 | Mar 29 2015 | $46.22 | $1.18 | 39.2x | +3% |
| FY2014 Q4 | Dec 31 2014 | $43.03 | $1.16 | 37.1x | -3% |
| FY2014 Q3 | Sep 28 2014 | $36.63 | $1.12 | 32.7x | -14% |
| FY2014 Q2 | Jun 29 2014 | $32.38 | $1.05 | 30.8x | -19% |
| FY2014 Q1 | Mar 30 2014 | $29.01 | $1.04 | 27.9x | -27% |
| FY2013 Q4 | - | $32.69 | $1.01 | 32.4x | -15% |
| FY2013 Q3 | Sep 29 2013 | $31.15 | $0.78 | 39.9x | +5% |
| FY2013 Q2 | Jun 30 2013 | $30.89 | $0.86 | 35.9x | -6% |
| FY2013 Q1 | Mar 31 2013 | $33.40 | $0.96 | 34.8x | -9% |
Average P/E for displayed period: 38.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZTS — Frequently Asked Questions
Quick answers to the most common questions about buying ZTS stock.
What is ZTS's P/E ratio?
Zoetis Inc. (ZTS) trailing twelve-month P/E ratio is 12.7x, based on TTM diluted EPS of $6.26. The 5-year average P/E is 35.1x and the historical range spans 19.6x to 57.1x.
Is ZTS stock overvalued or undervalued?
ZTS trades at 12.7x P/E, below its 5-year average of 35.1x. At the 0th percentile of its historical range (19.6x–57.1x), the stock is priced at a discount to its own history.
Is ZTS stock expensive?
No, ZTS is not expensive on a historical basis. The current P/E of 12.7x is below the 5-year average of 35.1x and sits at the 0th percentile of its valuation range.
What is ZTS's historical P/E range?
Over the past 5 years, ZTS's P/E ratio has ranged from 19.6x to 57.1x, with a median of 35.4x and an average of 35.1x. The current P/E of 12.7x places the stock at the 0th percentile of this range. Full historical data spans 2013–2026.
How does ZTS's P/E compare to the S&P 500?
ZTS trades at 12.7x P/E versus the S&P 500 median of 25.9x. The 51% discount to the market suggests lower growth expectations or perceived higher risk.
How does ZTS's valuation compare to Healthcare peers?
Zoetis Inc. P/E of 12.7x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ZTS's PEG ratio?
ZTS PEG ratio is 1.06, based on a P/E of 12.7x and EPS growth of 10.1%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is ZTS's earnings yield?
ZTS earnings yield is 7.89%, the inverse of its 12.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.